Pharmacological and clinical studies of ephedrine and other thermogenic agonists

被引:43
作者
Astrup, A [1 ]
Breum, L [1 ]
Toubro, S [1 ]
机构
[1] RVAU,CTR FOOD RES,DK-1958 FREDERIKSBERG C,DENMARK
来源
OBESITY RESEARCH | 1995年 / 3卷
关键词
appetite suppressant; caffeine; ephedrine; sympathomimetics; thermogenic agents;
D O I
10.1002/j.1550-8528.1995.tb00224.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
When given as a supplement to an energy restricted diet the sympathomimetic agent ephedrine, in combination with methylxanthines such as caffeine, improves fat loss by dual actions: a central suppression of appetite and peripheral stimulation of energy expenditure covered by fat oxidation, Mean weight loss was found to be 16.6 kg after 6 months when E+C was given as an adjuvant to an efficient hypoenergetic diet, which was 3,4 kg higher than in the placebo group, An additional 24 weeks treatment with E+C prevented relapse,In the first weeks of treatment E+C offset the hypotensive effect of energy restriction and weight loss, but the effect was transient, and after 8 weeks blood pressures were indistinguishable from those of the placebo group, E+C has no adverse effect on glucose and lipid metabolism, but has been shown to prevent the decline in HDL-cholesterol caused by weight loss, In a comparative trial the weight loss produced by E+C was similar to that of dexfenfluramine. More research on sympathomimetics and methylxanthines should he carried out to identify combinations with imp roved efficiency and safety, Moreover, more long-term trials and studies in males are required.
引用
收藏
页码:S537 / S540
页数:4
相关论文
共 12 条
  • [11] STICH V, 1993, INT J OBES S2, V17, P31
  • [12] TOUBRO S, 1993, INT J OBESITY, V17, pS69